Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone to improve safety learning in PTSD with HPA-axis dysregulation
2024-516427-13-00Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of hydrocortisone in post-traumatic stress disorder (PTSD) (3 arms), sponsored by Radboud University Medical Center. Primary endpoints: Early life adversity, HPA-axis functioning and 2 more. Planned start Oct 2024; status: authorised.
02
Drugs
hydrocortisone
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on 2024-516427-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516427-13-00.